Larsen & Toubro Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 17, 2025, 3:52 am

Competitors of Larsen & Toubro Ltd

All Competitor Stocks of Larsen & Toubro Ltd

Quarterly Result

Last Updated: August 1, 2025, 6:05 pm

Below is a detailed analysis of the quarterly data for Larsen & Toubro Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 63,679.00 Cr.. The value appears to be declining and may need further review. It has decreased from 74,392.00 Cr. (Mar 2025) to 63,679.00 Cr., marking a decrease of 10,713.00 Cr..
• For Expenses, as of Jun 2025, the value is 55,655.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 64,516.00 Cr. (Mar 2025) to 55,655.00 Cr., marking a decrease of 8,861.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 8,024.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9,876.00 Cr. (Mar 2025) to 8,024.00 Cr., marking a decrease of 1,852.00 Cr..
• For OPM %, as of Jun 2025, the value is 13.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00%.
• For Other Income, as of Jun 2025, the value is 1,357.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,610.00 Cr. (Mar 2025) to 1,357.00 Cr., marking a decrease of 253.00 Cr..
• For Interest, as of Jun 2025, the value is 2,488.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,419.00 Cr. (Mar 2025) to 2,488.00 Cr., marking an increase of 69.00 Cr..
• For Depreciation, as of Jun 2025, the value is 1,033.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,052.00 Cr. (Mar 2025) to 1,033.00 Cr., marking a decrease of 19.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 5,860.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8,014.00 Cr. (Mar 2025) to 5,860.00 Cr., marking a decrease of 2,154.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 26.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 4,318.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,156.00 Cr. (Mar 2025) to 4,318.00 Cr., marking a decrease of 1,838.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 26.30. The value appears to be declining and may need further review. It has decreased from 39.97 (Mar 2025) to 26.30, marking a decrease of 13.67.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:56 pm

Growth

Last Updated: September 5, 2025, 9:35 am

Balance Sheet

Last Updated: June 16, 2025, 11:48 am

Below is a detailed analysis of the balance sheet data for Larsen & Toubro Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 275.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 275.00 Cr..
• For Reserves, as of Mar 2025, the value is 97,381.00 Cr.. The value appears strong and on an upward trend. It has increased from 86,084.00 Cr. (Mar 2024) to 97,381.00 Cr., marking an increase of 11,297.00 Cr..
• For Borrowings, as of Mar 2025, the value is 132,409.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 116,322.00 Cr. (Mar 2024) to 132,409.00 Cr., marking an increase of 16,087.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 149,050.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 136,921.00 Cr. (Mar 2024) to 149,050.00 Cr., marking an increase of 12,129.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 379,114.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 339,602.00 Cr. (Mar 2024) to 379,114.00 Cr., marking an increase of 39,512.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 44,055.00 Cr.. The value appears strong and on an upward trend. It has increased from 42,964.00 Cr. (Mar 2024) to 44,055.00 Cr., marking an increase of 1,091.00 Cr..
• For CWIP, as of Mar 2025, the value is 2,589.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,045.00 Cr. (Mar 2024) to 2,589.00 Cr., marking a decrease of 456.00 Cr..
• For Investments, as of Mar 2025, the value is 54,805.00 Cr.. The value appears strong and on an upward trend. It has increased from 45,648.00 Cr. (Mar 2024) to 54,805.00 Cr., marking an increase of 9,157.00 Cr..
• For Other Assets, as of Mar 2025, the value is 277,665.00 Cr.. The value appears strong and on an upward trend. It has increased from 247,946.00 Cr. (Mar 2024) to 277,665.00 Cr., marking an increase of 29,719.00 Cr..
• For Total Assets, as of Mar 2025, the value is 379,114.00 Cr.. The value appears strong and on an upward trend. It has increased from 339,602.00 Cr. (Mar 2024) to 379,114.00 Cr., marking an increase of 39,512.00 Cr..

However, the Borrowings (132,409.00 Cr.) are higher than the Reserves (97,381.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Larsen & Toubro Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 109.36. This value is within the healthy range. It has increased from 93.96 (Mar 24) to 109.36, marking an increase of 15.40.
• For Diluted EPS (Rs.), as of Mar 25, the value is 109.28. This value is within the healthy range. It has increased from 93.88 (Mar 24) to 109.28, marking an increase of 15.40.
• For Cash EPS (Rs.), as of Mar 25, the value is 158.58. This value is within the healthy range. It has increased from 140.05 (Mar 24) to 158.58, marking an increase of 18.53.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 710.12. It has decreased from 746.01 (Mar 24) to 710.12, marking a decrease of 35.89.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 710.12. It has decreased from 746.01 (Mar 24) to 710.12, marking a decrease of 35.89.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,859.62. It has increased from 1,608.50 (Mar 24) to 1,859.62, marking an increase of 251.12.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 222.22. This value is within the healthy range. It has increased from 201.15 (Mar 24) to 222.22, marking an increase of 21.07.
• For PBIT / Share (Rs.), as of Mar 25, the value is 192.25. This value is within the healthy range. It has increased from 174.37 (Mar 24) to 192.25, marking an increase of 17.88.
• For PBT / Share (Rs.), as of Mar 25, the value is 171.46. This value is within the healthy range. It has increased from 149.25 (Mar 24) to 171.46, marking an increase of 22.21.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 128.62. This value is within the healthy range. It has increased from 113.26 (Mar 24) to 128.62, marking an increase of 15.36.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 109.34. This value is within the healthy range. It has increased from 95.00 (Mar 24) to 109.34, marking an increase of 14.34.
• For PBDIT Margin (%), as of Mar 25, the value is 11.94. This value is within the healthy range. It has decreased from 12.50 (Mar 24) to 11.94, marking a decrease of 0.56.
• For PBIT Margin (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has decreased from 10.84 (Mar 24) to 10.33, marking a decrease of 0.51.
• For PBT Margin (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 10. It has decreased from 9.27 (Mar 24) to 9.22, marking a decrease of 0.05.
• For Net Profit Margin (%), as of Mar 25, the value is 6.91. This value is within the healthy range. It has decreased from 7.04 (Mar 24) to 6.91, marking a decrease of 0.13.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.87. This value is below the healthy minimum of 8. It has decreased from 5.90 (Mar 24) to 5.87, marking a decrease of 0.03.
• For Return on Networth / Equity (%), as of Mar 25, the value is 15.39. This value is within the healthy range. It has increased from 15.12 (Mar 24) to 15.39, marking an increase of 0.27.
• For Return on Capital Employeed (%), as of Mar 25, the value is 14.89. This value is within the healthy range. It has increased from 14.70 (Mar 24) to 14.89, marking an increase of 0.19.
• For Return On Assets (%), as of Mar 25, the value is 3.96. This value is below the healthy minimum of 5. It has increased from 3.84 (Mar 24) to 3.96, marking an increase of 0.12.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.58. This value is within the healthy range. It has decreased from 0.65 (Mar 24) to 0.58, marking a decrease of 0.07.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.33. This value exceeds the healthy maximum of 1. It has increased from 1.32 (Mar 24) to 1.33, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has increased from 0.66 (Mar 24) to 0.71, marking an increase of 0.05.
• For Current Ratio (X), as of Mar 25, the value is 1.21. This value is below the healthy minimum of 1.5. It has decreased from 1.23 (Mar 24) to 1.21, marking a decrease of 0.02.
• For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.20 (Mar 24) to 1.18, marking a decrease of 0.02.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.87. This value is below the healthy minimum of 4. It has increased from 2.89 (Mar 24) to 3.87, marking an increase of 0.98.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 25.60. This value is within the healthy range. It has decreased from 32.29 (Mar 24) to 25.60, marking a decrease of 6.69.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.09. This value is within the healthy range. It has decreased from 25.18 (Mar 24) to 20.09, marking a decrease of 5.09.
• For Earning Retention Ratio (%), as of Mar 25, the value is 74.40. This value exceeds the healthy maximum of 70. It has increased from 67.71 (Mar 24) to 74.40, marking an increase of 6.69.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.91. This value exceeds the healthy maximum of 70. It has increased from 74.82 (Mar 24) to 79.91, marking an increase of 5.09.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 9.16. This value is within the healthy range. It has increased from 7.80 (Mar 24) to 9.16, marking an increase of 1.36.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.16. This value is within the healthy range. It has increased from 5.36 (Mar 24) to 6.16, marking an increase of 0.80.
• For Enterprise Value (Cr.), as of Mar 25, the value is 604,424.40. It has decreased from 633,678.46 (Mar 24) to 604,424.40, marking a decrease of 29,254.06.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.36. This value is within the healthy range. It has decreased from 2.87 (Mar 24) to 2.36, marking a decrease of 0.51.
• For EV / EBITDA (X), as of Mar 25, the value is 19.78. This value exceeds the healthy maximum of 15. It has decreased from 22.92 (Mar 24) to 19.78, marking a decrease of 3.14.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.35 (Mar 24) to 1.88, marking a decrease of 0.47.
• For Retention Ratios (%), as of Mar 25, the value is 74.39. This value exceeds the healthy maximum of 70. It has increased from 67.70 (Mar 24) to 74.39, marking an increase of 6.69.
• For Price / BV (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has decreased from 6.01 (Mar 24) to 4.92, marking a decrease of 1.09.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.35 (Mar 24) to 1.88, marking a decrease of 0.47.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness